Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (181-190 of 250) with videos related to

Pageof 25
Sort By:
Cancer Medicine|December 14, 2022
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)Min-Hee Ryu, Kyung Hee Lee, Lin Shen, et al.
Hepatology (Baltimore, Md.)|March 31, 2023
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancersChanghoon Yoo, Milind M Javle, Helena Verdaguer Mata, et al.
Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
Oncotarget|June 1, 2017
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimenChanghoon Yoo, Jihoon Kang, Kyu-Pyo Kim, et al.
Frontiers in Oncology|August 29, 2022
Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trialsMatthew Ledenko, Samuel O Antwi, Shiho Arima, et al.
Targeted Oncology|March 19, 2021
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched AnalysisYeonghak Bang, Changhoon Yoo, Sara Lonardi, et al.
Clinical Lung Cancer|May 23, 2015
Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative ResectionChanghoon Yoo, Shinkyo Yoon, Dae Ho Lee, et al.
Cancer Research and Treatment|September 4, 2020
Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract CancerHyung-Don Kim, Jwa Hoon Kim, Yeon-Mi Ryu, et al.
Journal of Hepatology|March 28, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 studyChanghoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, et al.
Nature Medicine|February 20, 2024
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trialHyung-Don Kim, Seyoung Jung, Ho Yeong Lim, et al.
Pageof 25

Showing results (181-190 of 250) with videos related to

Sort By:
Pageof 25
Cancer Medicine|December 14, 2022
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)Min-Hee Ryu, Kyung Hee Lee, Lin Shen, et al.
Hepatology (Baltimore, Md.)|March 31, 2023
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancersChanghoon Yoo, Milind M Javle, Helena Verdaguer Mata, et al.
Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
Oncotarget|June 1, 2017
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimenChanghoon Yoo, Jihoon Kang, Kyu-Pyo Kim, et al.
Frontiers in Oncology|August 29, 2022
Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trialsMatthew Ledenko, Samuel O Antwi, Shiho Arima, et al.
Targeted Oncology|March 19, 2021
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched AnalysisYeonghak Bang, Changhoon Yoo, Sara Lonardi, et al.
Clinical Lung Cancer|May 23, 2015
Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative ResectionChanghoon Yoo, Shinkyo Yoon, Dae Ho Lee, et al.
Cancer Research and Treatment|September 4, 2020
Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract CancerHyung-Don Kim, Jwa Hoon Kim, Yeon-Mi Ryu, et al.
Journal of Hepatology|March 28, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 studyChanghoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, et al.
Nature Medicine|February 20, 2024
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trialHyung-Don Kim, Seyoung Jung, Ho Yeong Lim, et al.
Pageof 25